Acrivon CHKs itself
The company is abandoning ovarian and bladder, but still sees a path in endometrial cancer.
The company is abandoning ovarian and bladder, but still sees a path in endometrial cancer.
The Artistry-7 Keytruda combo trial fails, spurring discontinuation in ovarian cancer.
The company is stepping back in second-line breast cancer.
First-in-human study listings include EOS-215 and RO7673396.
The company’s matching strategy for CB-010 will soon be put to the test.
Vobra-duo is discontinued at long last.
After Astra's EsoBiotec takeover the battle for uniqueness begins.
The honeymoon is over for Claudin18.2, as Elevation drops EO-3021.
YL217 will enter phase 1 before Sotio's similarly acting rival, licensed from Biocytogen.
While Sutro shows why it’s shelved luvelta-T.